CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 84 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,818,304 | +97.1% | 61,140 | +19.4% | 0.00% | – |
| Q2 2023 | $922,624 | +12.2% | 51,200 | 0.0% | 0.00% | – |
| Q1 2023 | $822,272 | -12.2% | 51,200 | 0.0% | 0.00% | – |
| Q4 2022 | $936,960 | -6.9% | 51,200 | 0.0% | 0.00% | – |
| Q3 2022 | $1,006,000 | +5.3% | 51,200 | 0.0% | 0.00% | – |
| Q2 2022 | $955,000 | +46.9% | 51,200 | +73.0% | 0.00% | – |
| Q1 2022 | $650,000 | -22.4% | 29,600 | +0.3% | 0.00% | – |
| Q4 2021 | $838,000 | +34.9% | 29,500 | 0.0% | 0.00% | – |
| Q3 2021 | $621,000 | +11.7% | 29,500 | 0.0% | 0.00% | – |
| Q2 2021 | $556,000 | +35.6% | 29,500 | +10.1% | 0.00% | – |
| Q1 2021 | $410,000 | +4.1% | 26,800 | -3.9% | 0.00% | – |
| Q4 2020 | $394,000 | -3.0% | 27,900 | +7.7% | 0.00% | – |
| Q3 2020 | $406,000 | -10.6% | 25,900 | 0.0% | 0.00% | – |
| Q2 2020 | $454,000 | +108.3% | 25,900 | +75.0% | 0.00% | – |
| Q1 2020 | $218,000 | -26.4% | 14,800 | +25.4% | 0.00% | – |
| Q4 2019 | $296,000 | +76.2% | 11,800 | +5.4% | 0.00% | – |
| Q3 2019 | $168,000 | -25.3% | 11,200 | +24.4% | 0.00% | – |
| Q2 2019 | $225,000 | – | 9,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |